For example, lenalidomide and pomalidomide lead to the degradation of the neo-substrates Ikaros (family zinc finger protein-1, IKZF1) and Aiolos (family zinc finger protein-3, IKZF3) transcriptional factors, thereby exhibiting an anti-myeloma activity48,49. The gene discussed is IKZF1; the disease is plasma cell myeloma.